Loading data for VCYT — first visit, this takes a few seconds.

Alerte

Veracyte Inc. Common Stoc... (VCYT)

NasdaqGM: VCYT · Prix en temps réel · USD

41.25

-1.35 (-3.17%)

À la clôture : Aug 18, 2026, 3:59 PM

42.05

+1.94%

Après-Bourse: 7:23 PM

-3.17% (1D)

Cours acheteur	33.3
Capitalisation boursière	3.32B
Chiffre d’affaires (ttm)	561.9M
Résultat net (ttm)	114.48M
Bêta	1.94
EPS (ttm)	1.4
Ratio P/E (ttm)	29.46
P/E prévisionnel	21.17
P/B (ttm)	2.50
P/S (ttm)	5.90
Earnings Date	Nov 3, 2026

Cours vendeur	59.52
Volume	1,667,950
Volume moy. (20D)	1,318,841
Ouverture	42.54
Clôture précédente	42.60
Fourchette du jour	41.04 - 43.12
Intervalle de 52 semaines	28.25 - 60.91
Analyste	n/a
Objectif de prix	n/a
Dividendes	n/a
Date ex-dividende	n/a

À propos de VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nC...

[En savoir plus]

Industrie Diagnostics & Research

Secteur Healthcare

Date d’introduction Oct 30, 2013

Employés 755

Bourse NasdaqGM

Symbole boursier VCYT

Site web https://www.veracyte.com

Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de Veracyte Common Stock s’élevait à 517.14M, soit une hausse de 16.01% par rapport aux 445.76M de l’année précédente. Le bénéfice s’élevait à 66.35M, soit une hausse de 174.89%.

États financiers

Surprise sur les résultats

Veracyte Common Stock a publié ses résultats trimestriels le Jul 30, 2026 :

Chiffre d’affaires de $150.32M est inférieur aux estimations de $0, avec 15.49% croissance en glissement annuel.

EPS de 0.54 dépasse les estimations de 0.11, avec 22.73% croissance en glissement annuel.

Prochaine publication des résultats

Veracyte Inc. Common Stock devrait publier ses résultats le Nov 3, 2026, pendant les heures de marché.
Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure

Actualités

2 semaines il y a · MarketBeat

Veracyte Q2 Earnings Call Highlights

Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD r...

2 semaines il y a · Simply Wall St.

Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?

Veracyte (VCYT) is back in focus after raising its 2026 revenue guidance to a range of US$590 million to US$596 million, and releasing detailed second quarter and first half earnings results. See our ...

2 semaines il y a · GuruFocus.com

Veracyte Inc (VCYT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Launches ...

Veracyte Inc (VCYT) raises full-year guidance after delivering 15% revenue growth and launching Prosigna and TrueMRD, positioning for long-term expansion.

2 semaines il y a · Zacks

Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of +25.58% and +4.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 semaines il y a · Insider Monkey

Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S. market saw a...

Page 1 de 2